The Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as a multicenter and multidisciplinary program to investigate the incidence, etiology, and pathophysiology of diabetes following acute pancreatitis (AP). The Chicago Clinical Center (CCC) of the T1DAPC is an interdisciplinary clinical-translational program led by the University of Illinois Chicago (UIC) and includes Northwestern University as a satellite site. The CCC is well-integrated into the T1DAPC and has made significant contributions to its objectives. It provides considerable leadership in the organization, participates in Committees and Working Groups, and contributes to the development and execution of ancillary studies and publications. Specifically, the CCC has been the leading center in enrollment of AP patients into the Diabetes Related to Acute Pancreatitis and its Mechanisms (DREAM) study, a prospective longitudinal observational clinical study of the T1DAPC. Our proposal leverages our large AP cohort and our multidisciplinary team with complementary expertise in pancreatology, diabetes, gut microbiome, metabolome, artificial intelligence (AI), and diet, with a proven track record of collaboration. We propose the following two specific aims to meet the goals of RFA-DK-25-017 in the next five years of funding. Aim 1. Continue to contribute to the assembly of the DREAM cohort, longitudinal follow-up of its study participants, and completion of its ancillary studies. Aim 2. Define the mechanisms of AP-driven diabetes by proposing the following three ancillary studies: Aim 2.1. Determine the association of gut microbiome and metabolome with the development of AP-driven diabetes, Aim 2.2. Develop novel, precise, reliable, and trustworthy artificial intelligence (AI) algorithms for early prediction of AP-driven diabetes, and Aim 2.3. Define the association of social vulnerability with the development of AP-driven diabetes. We are well-positioned to execute these specific aims with our interdisciplinary expertise, well-established clinical and research infrastructure, extremely productive patient enrollment profile, streamlined sample processing, and transfer. In addition, we will continue to contribute to the success of the T1DAPC with our existing leadership roles, active participation in T1DAPC Committees and Working Groups, and strong collaborations within the T1DAPC.